Health & Fitness
Health and Fitness
Health and Fitness
Mon, April 11, 2011Sun, April 10, 2011Sat, April 9, 2011Fri, April 8, 2011Thu, April 7, 2011Wed, April 6, 2011Tue, April 5, 2011Mon, April 4, 2011Sun, April 3, 2011Sat, April 2, 2011Fri, April 1, 2011Thu, March 31, 2011Wed, March 30, 2011Tue, March 29, 2011Mon, March 28, 2011Sun, March 27, 2011Fri, March 25, 2011Thu, March 24, 2011Wed, March 23, 2011Tue, March 22, 2011Mon, March 21, 2011Sun, March 20, 2011Fri, March 18, 2011AVEO Pharmaceuticals, Inc. to Present at the Leerink Swann Cancer Roundtable Conference
Published in Health and Fitness on Thursday, March 31st 2011 at 3:40 GMT by Market Wire
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to participate in a panel titled aProstate and GU Cancersa at 12:15 p.m. (EDT), as well as present a corporate overview on AVEO at 1:15 p.m. (EDT), at the Leerink Swann Cancer Roundtable conference on Thursday, April 7, 2011 at the Roosevelt Hotel in New York City.
A live webcast of AVEO's presentation can be accessed by visiting the investors section of the company's website at investor.aveopharma.com. A replay of the webcast will be archived on the AVEO website for two weeks following the presentation.
About AVEO
AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patientsa™ lives. The companya™s lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEOa™s second most advanced product candidate, ficlatuzumab (AV-299), is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEOa™s proprietary Human Response Platforma" is designed to offer the company a unique advantage in cancer drug development and has provided a discovery engine for multiple therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the companya™s website at www.aveopharma.com.
